Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

This study has been completed.
Information provided by (Responsible Party):
Janssen R&D Ireland Identifier:
First received: March 24, 2011
Last updated: March 31, 2016
Last verified: March 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)